CoChat

Early phase clinical trials to identify optimal dosing and safety

Open access
Cook, Natalie, Hansen, Aaron R., Siu, Lillian L., Abdul Razak, Albiruni R. · 2015 · Molecular Oncology
Cited by 134

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The purpose of early stage clinical trials is to determine the recommended dose and toxicity profile of an investigational agent or multi‐drug combination. Molecularly targeted agents (MTAs) and immunotherapies have distinct toxicities from chemotherapies that are often not dose dependent and can lead to chronic and sometimes unpredictable side effects. Therefore utilizing a dose escalation method that has toxicity based endpoints may not be as appropriate for determination of recommended dose, and alternative parameters such as pharmacokinetic or pharmacodynamic outcomes are potentially appealing options. Approaches to enhance safety and optimize dosing include improved preclinical models and assessment, innovative model based design and dose escalation strategies, patient selection, the use of expansion cohorts and extended toxicity assessments. Tailoring the design of phase I trials by adopting new strategies to address the different properties of MTAs is required to enhance the development of these agents. This review will focus on the limitations to safety and dose determination that have occurred in the development of MTAs and immunotherapies. In addition, strategies are proposed to overcome these challenges to develop phase I trials that can more accurately define the recommended dose and identify adverse events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2014.07.025

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 134

Metadata

Authors
Cook, N., Hansen, A. R., Siu, L. L., & Abdul Razak, A. R.
Venue
Molecular Oncology
Publisher
Wiley
Published
2014-08-14
Volume
9
Issue
5
Pages
997-1007
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W1971685703
Cited by
134
References
14
FWCI
5.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early phase clinical trials to identify optimal dosing and safety. https://app.cochat.ai/papers/10.1016/j.molonc.2014.07.025
The paper
Cook, N., Hansen, A. R., Siu, L. L., & Abdul Razak, A. R. (2015). Early phase clinical trials to identify optimal dosing and safety. Molecular Oncology. https://doi.org/10.1016/j.molonc.2014.07.025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.